18 and older, any sex, with Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
% Time in Target Range Defined as 3.9-10mmol/lPrimary· 6 months
Interstitial blood glucose will be measured every 5 minutes via CGM for a period of six months (original plan)
The study was terminated early. Only two participants entered the allocated study arm and remained in the study for two weeks.
Group
Value
95% CI
BiAP, Fixed Bolus Calculator
70
BiAP, ABC4D
77
Sponsor's own description
The purpose of the study is to evaluate the safety and effectiveness of a closed-loop insulin delivery system (also known as an artificial pancreas) which is made up of three components that communicate with each other:
1. A glucose sensor that measures glucose every 5 minutes
2. A control algorithm that calculates the required insulin dose
3. An insulin pump that delivers the insulin calculated
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Other recruiting trials for Diabetes Mellitus, Type 1
Currently open trials in the same condition.
NCT07325461 — Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes
· NA
· recruiting
NCT07305805 — A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes
· Phase 1
· recruiting
NCT06282055 — Trajectories in Insulin Sensitivity Across MEnstrual cycleS in Women With Type 1 Diabetes
· recruiting
NCT06325202 — Closed Loop and Education for Hypoglycemia Awareness Restoration
· NA
· recruiting
NCT07160816 — A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar
· recruiting
Other Imperial College London trials
Trials by the same sponsor.
NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH
· NA
· not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants
· Phase 1
· not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing
· NA
· not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy
· Phase 2
· not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 5 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03740698.